Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > vericiguat

vericiguat

pharmaceutical raw materials
vericiguat structure

vericiguat 

structure
  • CAS No:

    1350653-20-1

  • Formula:

    C19H16F2N8O2

  • Chemical Name:

    vericiguat

  • Synonyms:

    vericiguat;BAY1021189;Carbamic acid, N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-, methyl ester;Vericiguat (BAY 1021189);MK-1242;methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate (Vericiguat);Inhibitor,BAY-1021189,BAY 1021189,inhibit,Guanylate Cyclase,Vericiguat;Vericygua

  • Categories:

    Pharmaceutical Intermediates  >  Bulk Drug Intermediates

Description

Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator.- Soluble guanylate cyclase (sGC) is an enzyme that is activated by nitric oxide (NO). The activation initiates a signaling cascade which converts guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). cGMP levels increase & protein kinase G (PKG) is activated, resulting in a decrease of intracellular free Ca++ -> vascular smooth muscle cell relaxation.- However, individuals with HF have reduced NO levels. Vericiguat, as a sGC stimulator, increases the enzymatic activity of sGC to generate cGMP independently of NO and enhances sGC sensitivity to endogenous NO.Vericiguat is the 2nd drug in this class and follows riociguat ADEMPAS, which has been approved for treating pulmonary arterial hypertension.SOCRATES-REDUCED was a phase II dose-finding trial of vericiguat in HF-rEF. The primary endpoint, change in NTproBNP over 12 weeks, was not statistically significant compared to placebo. A secondary exploratory analysis suggested a dose-response relationship in which higher doses of vericiguat were associated with greater reductions in NTproBNP levels.


ChEBI: Vericiguat is a pyrazolopyridine that is 5-fluoro-1H-pyrazolo[3,4-b]pyridine in which the amino hydrogen at position 1 has been substituted by a 2-fluorobenzyl group and the hydrogen at position 3 has been substituted by a 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl group. It is a soluble guanylate cyclase stimulator which is used for treatment of chronic heart failure. It has a role as a soluble guanylate cyclase activator, a vasodilator agent and an antihypertensive agent. It is an aminopyrimidine, a pyrazolopyridine, a carbamate ester and an organofluorine compound.

vericiguat Basic Attributes

426.38

426.38

Light yellow to brown

Characteristics

1.63±0.1 g/cm3(Predicted)

535.9±50.0 °C(Predicted)

10.61±0.70(Predicted)

Store at 0-8 °C

vericiguat Use and Manufacturing

Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator that enhances the cyclic guanosine monophosphate (GMP) production pathway, by directly stimulating soluble guanylate cyclase activity, as well as sensitizing soluble guanylate cyclase to endogenous NO. It was initially developed for potential to reduce mortality and morbidity associated with chronic heart failure with reduced ejection fraction.


Vericiguat is used on targeting cyclic guanosine monophosphate in the treatment of heart failure.

Recommended Suppliers of vericiguat

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.